表 3.

血浆置换联合疗法治疗新月体型IgA肾病患者有效性分析

Efficacy of PLEX on primary and secondary outcomes

Outcomes	PLEX+IS group, n(%)	IS group, n(%)	HR (95%CI)	P
PLEX, plasma exchange therapy; IS, immunosuppressants; ESKD, end-stage kidney disease. *P was calculated using survival analysis (HR)；Other P values were caculated using Pearson χ2 or Fisher exact tests.
Primary outcomes
ESKD	16 (69.6)	13 (56.5)	0.959 (0.458－2.010)	0.912*
Second outcomes
All cause of death	2 (8.7)	1 (4.3)	1.048 (0.899－1.221)	0.555
ESKD at 6 months	8 (34.8)	10 (43.5)	0.867 (0.544－1.382)	0.546
ESKD at 12 months	10 (43.5)	10 (43.5)	1.000 (0.602－1.660)	1.000
Dialysis-free at 3 months	3 (50.0)	2 (28.6)	1.429 (0.565－3.611)	0.447
Dialysis-free at 12 months	1 (16.7)	1 (14.3)	1.029 (0.644－1.643)	0.909